About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT05101083

Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids

This clinical investigation is designed to compare audiological performance (i.e., measurements of sound quality and speech understanding) between Starkey's new receiver-in-canal device and a commerci...

Lead sponsor: Starkey Laboratories, Inc•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Starkey Laboratories, Inc

Starkey is investigating a new hearing aid with several new audiological features. These features have been assessed for benefit, individually, but this clinical investigation will serve as a test for safety and efficacy with all hearing aid features, together. The design of this study is a single-blinded, crossover design and will be conducted at Starkey's headquarters in Eden Prairie, MN.

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adults, minimum age of 18
•Native English speakers
•Ability to complete questionnaires and laboratory assessments
•Symmetric, mild to moderately-severe sensorineural hearing loss
•Informed consent completed with signature

Exclusion Criteria

•Inability to visit the Starkey Headquarters building for testing
•Central or middle ear hearing problems
•Medical contraindications to wearing hearing aids
•Learning disability, major cognitive handicap, or serious neurological or psychiatric disease that would prevent or restrict participation, as determined by the PI or designee

Related studies

RECRUITINGPhase 1/2

A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

NCT07288580 · Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Tinnitus Patient Preferences Survey

NCT06782308 · Tinnitus, Subjective, Tinnitus, Bilateral, and more

RECRUITINGPhase 2

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183 · Hearing Loss, Head and Neck Cancer

Otoferlin Gene-mediated Hearing Loss Natural History Study

NCT05572073 · Sensorineural Hearing Loss, Bilateral

MED-EL HEARING SOLUTIONS (MEHS): AN OBSERVATIONAL STUDY

NCT05668338 · Hearing Loss

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 18, 2022Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment34

Start dateOct 2021

Last updatedJan 18, 2022

Condition

Hearing Loss, Sensorineural Hearing Loss

Locations shown

Starkey

Eden Prairie, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 18, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions